SARM1 Inhibition: A Master Stroke Against Neurodegenerative Disease?

Axonal pathology is an early feature of many neurodegenerative diseases. Research that began with investigations into the mechanism underlying Wallerian degeneration of damaged axons has revealed the crucial importance of NAD⁺ metabolism in axon survival. This work identified key players that dictate the fate of axons, including the pro-survival factors NMNAT2 and STMN2 and the degeneration-promoting factors DLK and SARM1 (1). SARM1 is now recognized as the primary axon killer through its NAD⁺-consuming enzymatic activity, and SARM1 inhibitors that protect against axon degeneration in pre-clinical studies are generating great excitement (2, 3).

GeneTex is expanding its inventory of antibodies for axon degeneration research with the addition of new recombinant rabbit antibodies against SARM1 (see below). We also offer antibodies against DLK and STMN2 (see below). To learn more about GeneTex’s catalog of products for neurodegenerative disease research, please click here or visit www.genetex.com.